|Inclusion Criteria:||1) Age > 18 years old. This study was written for an adult population (the incidence of this disease in the pediatric population is rare.|
2) Recurrent EOC or PPC with histologic confirmation of the original tumor. Recurrent disease may be manifested as an elevated CA-125 using the following criteria (Vergote et al., 2000): (A) Increase in CA-125 to at least 2x the ULN (assayed on 2 occasions at least 7 days apart) for subjects with a history of normal pre-treatment values or values that normalized with most recent treatment. -OR- (B) Increase in CA-125 to 2x the lowest observed value on most recent treatment (assayed on two occasions at least 7 days apart) for subjects whose CA-125 did not normalize with most recent treatment.
3) Platinum-resistant disease, defined as recurrence less than six months after discontinuation of treatment with platinum therapy or platinum-refractory disease, defined as progression on a platinum-containing regimen.
4) A treatment-free interval of at least three weeks for cytotoxic therapies, radiation therapy, or other experimental drugs prior to first treatment on this protocol.
5) A Zubrod performance status of two or less.
6) Patients with known hypersensitivity to platinum compounds, who have failed a desensitization regimen, or in the opinion of the investigator, are not good candidates for desensitization, are eligible.